Compare AXGN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | AAPG |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2013 | 2024 |
| Metric | AXGN | AAPG |
|---|---|---|
| Price | $48.47 | $19.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $42.33 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 1.1M | 3.7K |
| Earning Date | 04-28-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $225,208,000.00 | N/A |
| Revenue This Year | $20.57 | $290.34 |
| Revenue Next Year | $16.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.21 | N/A |
| 52 Week Low | $13.64 | $16.36 |
| 52 Week High | $49.93 | $48.45 |
| Indicator | AXGN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 65.83 | 55.27 |
| Support Level | $29.48 | $18.56 |
| Resistance Level | N/A | $20.40 |
| Average True Range (ATR) | 2.65 | 0.42 |
| MACD | 0.66 | 0.15 |
| Stochastic Oscillator | 88.91 | 92.75 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.